Journal
NEURON
Volume 51, Issue 4, Pages 455-466Publisher
CELL PRESS
DOI: 10.1016/j.neuron.2006.07.006
Keywords
-
Categories
Funding
- Biotechnology and Biological Sciences Research Council [S19916] Funding Source: Medline
- NIDA NIH HHS [K02 DA000286, DA15916, R01 DA011322, P01 DA015916, DA11322, DA00286] Funding Source: Medline
- NIMH NIH HHS [MH49428, R01 MH049428, K05 MH065670, MH065670, R37 MH049428] Funding Source: Medline
- Biotechnology and Biological Sciences Research Council [S19916] Funding Source: researchfish
Ask authors/readers for more resources
Balanced control of neuronal activity is central in maintaining function and viability of neuronal circuits. The endocannabinoid system tightly controls neuronal excitability. Here, we show that endocannabinoids directly target hippocampal glutamatergic neurons to provide protection against acute epileptiform seizures in mice. Functional CB1 cannabinoid receptors are present on glutamatergic terminals of the hippocampal formation, colocalizing with vesicular glutamate transporter 1 (VGluT1). Conditional deletion of the CB1 gene either in cortical glutamatergic neurons or in forebrain GABAergic neurons, as well as virally induced deletion of the CB1 gene in the hippocampus, demonstrate that the presence of CB1 receptors in glutamatergic hippocampal neurons is both necessary and sufficient to provide substantial endogenous protection against kainic acid (KA)-induced seizures. The direct endocannabinoid-mediated control of hippocampal glutamatergic neurotransmission may constitute a promising therapeutic target for the treatment of disorders associated with excessive excitatory neuronal activity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available